Akses terbuka Jurnal SINTA 1
Cancer Immunotherapy: A Review
The Indonesian Biomedical Journal · Vol. 8 No. 1 (2016) · hlm. 1–1
- ISSN
- 2085-3297, 2355-9179
- Terbit
- 2016-04-01
- Penerbit
- Secretariat of The Indonesian Biomedical Journal
- Bahasa
- en
Abstrak
BACKGROUND: The goals of treating patients with cancer are to cure the disease, prolong survival, and improve quality of life. Immune cells in the tumor microenvironment have an important role in regulating tumor progression. Therefore, stimulating immune reactions to tumors can be an attractive therapeutic and prevention strategy.CONTENT: During immune surveillance, the host provides defense against foreign antigens, while ensuring it limits activation against self antigens. By targeting surface antigens expressed on tumor cells, monoclonal antibodies have demonstrated efficacy as cancer therapeutics. Recent successful antibody-based strategies have focused on enhancing antitumor immune responses by targeting immune cells, irrespective of tumor antigens. The use of antibodies to block pathways inhibiting the endogenous immune response to cancer, known as checkpoint blockade therapy, has stirred up a great deal of excitement among scientists, physicians, and patients alike. Clinical trials evaluating the safety and efficacy of antibodies that block the T cell inhibitory molecules cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) have reported success in treating subsets of patients. Adoptive cell transfer (ACT) is a highly personalized cancer therapy that involve administration to the cancer-bearing host of immune cells with direct anticancer activity. In addition, the ability to genetically engineer lymphocytes to express conventional T cell receptors or chimeric antigen receptors has further extended the successful application of ACT for cancer treatment.SUMMARY: For cancer treatment, 2011 marked the beginning of a new era. The underlying basis of cancer immunotherapy is to activate a patient’s own T cells so that they can kill their tumors. Reports of amazing recoveries abound, where patients remain cancer-free many years after receiving the therapy. The idea of harnessing immune cells to fight cancer is not new, but only recently have scientists amassed enough clinical data to demonstrate what a game-changer cancer immunotherapy can be. This field is no stranger to obstacles, so the future looks very promising indeed.KEYWORDS: immune checkpoint, adoptive cell transfer, neoantigen, monoclonal antibody
Kata kunci
Jaringan kolaborasi para penulis
40 penulis · 145 tautan kepenulisan bersama · 70 lintas organisasi · menampilkan 40 yang paling banyak terhubung
Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.
- Hasanuddin University
- Padjadjaran University
- PT Prodia StemCell Indonesia (Indonesia)
- Universitas Trisakti
- Udayana University
- University of Indonesia
- Universitas Airlangga
- Organisasi lain
- Organisasi berbeda
- Organisasi sama
- Afiliasi tidak diketahui
- Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
| Rekan penulis | Organisasi | Artikel bersama |
|---|---|---|
| Suryani As’ád | Hasanuddin University | 15 |
| Gatot Susilo Lawrence | Hasanuddin University | 7 |
| Ferry Sandra | Universitas Trisakti | 7 |
| Yani Lina | Hasanuddin University | 6 |
| Ilhamjaya Patellongi | Hasanuddin University | 6 |
| Irma Ruslina Defi | Padjadjaran University | 6 |
| Cynthia Retna Sartika | PT Prodia StemCell Indonesia (Indonesia) | 5 |
| Anwar Santoso | Udayana University | 4 |
| Syakib Bakri | Hasanuddin University | 4 |
| Melisa Intan Barliana | Padjadjaran University | 4 |
| Keri Lestari | Padjadjaran University | 4 |
| Teguh Ranakusuma | University of Indonesia | 3 |
| Irawan Yusuf | Hasanuddin University | 3 |
| Rima Haifa | PT Prodia StemCell Indonesia (Indonesia) | 3 |
| Trilis Yulianti | Hasanuddin University | 3 |
| Irma Rahayu Latarissa | Padjadjaran University | 3 |
| Ida Paulina Sormin | Hasanuddin University | 3 |
| Erizal Sugiono | Hasanuddin University | 3 |
| Keri Lestari Dandan | Padjadjaran University | 3 |
| Lucia Herminawati | Hasanuddin University | 3 |
| Aziiz Mardanarian Rosdianto | Padjadjaran University | 3 |
| Rina Triana | Padjadjaran University | 3 |
| Yenny Surjawan | Hasanuddin University | 2 |
| Mansyur Arief | Hasanuddin University | 2 |
| Andri Hidayat | Hasanuddin University | 2 |
| Ahmad Faried | Padjadjaran University | 2 |
| Marsetio Donosepoetro | Universitas Airlangga | 2 |
| Burhanuddin Bahar | Hasanuddin University | 2 |
| Widjaja Lukito | SEAMEO Regional Center for Food and Nutrition | 2 |
| Indriyanti Rafi Sukmawati | Hasanuddin University | 2 |
| Antonia Anna Lukito | Hasanuddin University | 2 |
| Mansyur Arif | Hasanuddin University | 2 |
| Anna Meilana | Padjadjaran University | 2 |
| Made Putra Semadhi | Padjadjaran University | 2 |
| Candra Ninghayu | Hasanuddin University | 1 |
| Cissy Bana Kartasasmita | Padjadjaran University | 1 |
| Irmansyah Irmansyah | National Research and Innovation Agency | 1 |
Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.